Evidence map›Paper›PMID 29805739›Full record

ArticleOncotarget2018

Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.

Richard Kim, Domenico Coppola, Emilie Wang, Young Doo Chang, Yuhree Kim, Daniel Anaya, Dae Won Kim

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04720131 (Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer), which is not on this map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04720131 phase2completednot on this mapstarted 2021, after this paper: background citation

Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study.

TypeinterventionalSponsorBeijing Friendship HospitalRan2021 to 2023Enrolled28ConditionsBiliary Tract Cancer, Anti-PD-1 Therapy, Targeted Molecular Therapy, CapecitabineArmsCamrelizumab, apatinib, Capecitabine
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.Journal of experimental & clinical cancer research : CR · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.Cellular and molecular gastroenterology and hepatology · 2020
    Article
  18. Immunobiology of cholangiocarcinoma.JHEP reports : innovation in hepatology · 2019
    Review
  19. The role of tumour microenvironment: a new vision for cholangiocarcinoma.Journal of cellular and molecular medicine · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Richard KimDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Domenico CoppolaDepartment of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA.
Emilie WangDepartment of Internal Medicine, University of South Florida, Tampa, FL, USA.
Young Doo ChangDepartment of Supportive Care, Moffitt Cancer Center, Tampa, FL, USA.
Yuhree KimDepartment of Population Medicine, Harvard Medical School, Boston, MA, USA.
Daniel AnayaDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Dae Won KimDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Moffitt Cancer Center · USHarvard University · USUniversity of South Florida · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

Cholangiocarcinoma is a malignancy arising from the biliary tract epithelial cells with poor prognosis. Tumor infiltrating lymphocytes (TIL)s and programmed cell death receptor ligand 1 (PD-L1) have a prognostic impact in various solid tumors. We aimed to investigate TILs and PD-L1 expression and their clinical relevance in cholangiocarcinoma. Tumor samples from 44 patients with resected and histologically verified extrahepatic cholangiocarcinoma were evaluated for CD8, CD45RO and PD-L1 expression, and their correlations with clinicopathological data and survival data were analyzed. Total 44 extrahepatic cholangiocarcinoma tissues were evaluated. CD8+ tumor infiltrating lymphocytes (TIL)s were observed in 30 (68%) tumors. Among them, 14 had CD8+CD45RO+ TILs. PD-L1 was expressed on cancer cells in 10 (22.7%) tumors in 34 evaluable extrahepatic cholangiocarciniomas. The presence of CD8+ TILs or CD8+CD45RO+ TILs was not associated with clinical staging or tumor differentiation. Extrahepatic cholangiocarcinoma with CD8+CD45RO+ TILs had longer overall survival (OS) on univariate (

Indexed as

cholangiocarcinomaPD-L1tumor infiltrating lymphocytestumor microenvironment

Identifiers

PMID29805739
PMCPMC5955104
OpenAlexW2802975351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.